Skip to Main Content
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
book

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

by Honghui Zhou, Diane R. Mould
March 2019
Intermediate to advanced content levelIntermediate to advanced
496 pages
15h
English
Wiley
Content preview from Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

12Pharmacokinetics‐Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease

Diane R. Mould1Richard N. Upton2 and Jessica Wojciechowski3

1Projections Research Inc., Phoenixville, PA, USA

2University of South Australia, School of Pharmacy and Medical Sciences, Adelaide, SA, Australia

3Pfizer Inc., Groton, CT, USA

12.1 Introduction

The pharmacokinetics (PK) of monoclonal antibodies (mAbs) exhibit substantial differences from that of chemical agents. The clearance (CL) mechanisms for mAbs differ from routes commonly reported for chemical therapeutics, and the effects of demographic characteristics, patient characteristics, and concomitant medications on the pharmacokinetic behavior of such agents may be quite distinct. Furthermore, the pharmacodynamics (PD) of mAbs often impact pharmacokinetic behavior, resulting in complex pharmacokinetic and pharmacodynamic behavior. Consequently, it is important to understand the unique characteristics of mAb pharmacokinetics as well as the pharmacology of the agent and aspects of the therapeutic area to optimally utilize therapeutic mAbs [1].

The first mAb (Orthoclone, OKT3) was approved for use in the treatment of acute rejection for renal transplant in 1986. Since that time, the number of mAbs in development and on the market has grown, and the class has expanded to cover antibodies, antibody fragments, antibody‐fusion proteins, antibody‐drug conjugates, and other forms. As a murine mAb, OKT3 taught a lot about anti‐drug ...

Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
and much more.
Start your free trial

You might also like

Applied Computing in Medicine and Health

Applied Computing in Medicine and Health

Dhiya Al-Jumeily, Abir Hussain, Conor Mallucci, Carol Oliver
Informatics for Health Professionals

Informatics for Health Professionals

Kathleen Mastrian, Dee McGonigle
Nanostructures for Novel Therapy

Nanostructures for Novel Therapy

Denisa Ficai, Alexandru Mihai Grumezescu

Publisher Resources

ISBN: 9781119289197Purchase book